Home > About Histogen > News - 2011

<< Back

Histogen Wins Motion for Summary Judgment in Patent Case, Defeating SkinMedica's
Claims

Histogen Wins Patent Ruling

David Nassif Joins Histogen as President and CFO

Hypoxia Induces Multipotency in Skin Cells, Proteins Produced Trigger Cancer Stem Cell Death

Histogen's proprietary tissue-engineering process is utilized for manufacturing all of Histogen's products. Newborn cells are placed into a bioreactor and conditioned with a liquid media.
  • HSC's components have recently been shown to be critical for new hair follicle formation
  • The field of stem cell research is rapidly expanding
  • Histogen scientists have developed regenerative medical technologies without the use of stem cells or animal serum
© Histogen Inc., CA 92121